Under such a scenario, the co‐targeting of FAK and the BRD4‐MYC axis may be of high therapeutic promise, as there is a functional interdependence between the integrin‐FAK and BRD4‐MYC, a potential “Achilles' heel” for CRC. The gene discussed is PTK2; the disease is colorectal carcinoma.